These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 36058033)

  • 1. Associations between the interleukin-6 rs1800795 G/C and interleukin-6 receptor rs12083537 A/G polymorphisms and response to disease-modifying antirheumatic drugs in rheumatoid arthritis: A meta-analysis.
    Lee YH; Song GG
    Int Immunopharmacol; 2022 Nov; 112():109184. PubMed ID: 36058033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-6-receptor polymorphisms rs12083537, rs2228145, and rs4329505 as predictors of response to tocilizumab in rheumatoid arthritis.
    Enevold C; Baslund B; Linde L; Josephsen NL; Tarp U; Lindegaard H; Jacobsen S; Nielsen CH
    Pharmacogenet Genomics; 2014 Aug; 24(8):401-5. PubMed ID: 24978393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic Biomarkers as Predictors of Response to Tocilizumab in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.
    Janahiraman S; Too CL; Lee KW; Shahril NS; Leong CO
    Genes (Basel); 2022 Jul; 13(7):. PubMed ID: 35886067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A single nucleotide polymorphism of IL6-receptor is associated with response to tocilizumab in rheumatoid arthritis patients.
    Luxembourger C; Ruyssen-Witrand A; Ladhari C; Rittore C; Degboe Y; Maillefert JF; Gaudin P; Marotte H; Wendling D; Jorgensen C; Cantagrel A; Constantin A; Nigon D; Touitou I; Gottenberg JE; Pers YM
    Pharmacogenomics J; 2019 Aug; 19(4):368-374. PubMed ID: 30647443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of the ABCB1 C3435T polymorphism with responsiveness to and toxicity of DMARDs in rheumatoid arthritis : A meta-analysis.
    Lee YH; Bae SC; Song GG
    Z Rheumatol; 2016 Sep; 75(7):707-15. PubMed ID: 26184955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of IL6R gene polymorphisms in the effectiveness to treatment with tocilizumab in rheumatoid arthritis.
    Maldonado-Montoro M; Cañadas-Garre M; González-Utrilla A; Ángel Calleja-Hernández M
    Pharmacogenomics J; 2018 Jan; 18(1):167-172. PubMed ID: 27958380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional FCGR3A 158 V/F and IL-6 -174 C/G polymorphisms predict response to biologic therapy in patients with rheumatoid arthritis: a meta-analysis.
    Lee YH; Bae SC; Song GG
    Rheumatol Int; 2014 Oct; 34(10):1409-15. PubMed ID: 24728031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The combination of IL-6 and its soluble receptor is associated with the response of rheumatoid arthritis patients to tocilizumab.
    Diaz-Torne C; Ortiz MDA; Moya P; Hernandez MV; Reina D; Castellvi I; De Agustin JJ; Fuente D; Corominas H; Sanmarti R; Zamora C; Cantó E; Vidal S
    Semin Arthritis Rheum; 2018 Jun; 47(6):757-764. PubMed ID: 29157669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of interleukin-6 promoter polymorphism with rheumatoid arthritis: a meta-analysis with trial sequential analysis.
    Shao M; Xie H; Yang H; Xu W; Chen Y; Gao X; Guan S; Xu S; Shuai Z; Pan F
    Clin Rheumatol; 2022 Feb; 41(2):411-419. PubMed ID: 34494214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pilot study of single nucleotide polymorphisms in the interleukin-6 receptor and their effects on pre- and post-transplant serum mediator level and outcome after allogeneic stem cell transplantation.
    Tvedt THA; Hovland R; Tsykunova G; Ahmed AB; Gedde-Dahl T; Bruserud Ø
    Clin Exp Immunol; 2018 Jul; 193(1):130-141. PubMed ID: 29513361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genotype at the sIL-6R A358C polymorphism does not influence response to anti-TNF therapy in patients with rheumatoid arthritis.
    Hassan B; Maxwell JR; Hyrich KL; ; Barton A; Worthington J; Isaacs JD; Morgan AW; Wilson AG
    Rheumatology (Oxford); 2010 Jan; 49(1):43-7. PubMed ID: 19926672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The CC homozygosis of the -174G>C IL-6 polymorphism predicts a lower efficacy of rituximab therapy in rheumatoid arthritis.
    Fabris M; Quartuccio L; Lombardi S; Saracco M; Atzeni F; Carletto A; Cimmino M; Fabro C; Pontarini E; Pellerito R; Bambara LM; Sarzi-Puttini P; Cutolo M; Manfredi M; Benucci M; Morassi P; Fischetti F; Padovan M; Govoni M; Curcio F; Tonutti E; De Vita S
    Autoimmun Rev; 2012 Mar; 11(5):315-20. PubMed ID: 20974296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-6-174G > C (rs1800795) polymorphism distribution and its association with rheumatoid arthritis: A case-control study and meta-analysis.
    Dar SA; Haque S; Mandal RK; Singh T; Wahid M; Jawed A; Panda AK; Akhter N; Lohani M; Areeshi MY; Rai G; Datt S; Bhattacharya SN; Ramachandran VG; Das S
    Autoimmunity; 2017 May; 50(3):158-169. PubMed ID: 28010120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Associations between interleukin-10 polymorphisms and susceptibility to rheumatoid arthritis: a meta-analysis.
    Lee YH; Bae SC; Choi SJ; Ji JD; Song GG
    Mol Biol Rep; 2012 Jan; 39(1):81-7. PubMed ID: 21553228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Value of
    Sainz L; Riera P; Moya P; Bernal S; Casademont J; Díaz-Torné C; Millán AM; Park HS; Lasa A; Corominas H
    J Pers Med; 2022 Dec; 13(1):. PubMed ID: 36675722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study.
    Genovese MC; McKay JD; Nasonov EL; Mysler EF; da Silva NA; Alecock E; Woodworth T; Gomez-Reino JJ
    Arthritis Rheum; 2008 Oct; 58(10):2968-80. PubMed ID: 18821691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-4, interleukin-4 receptor, and interleukin-18 polymorphisms and rheumatoid arthritis: a meta-analysis.
    Song GG; Bae SC; Kim JH; Lee YH
    Immunol Invest; 2013; 42(6):455-69. PubMed ID: 23883285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tocilizumab in the treatment of adult rheumatoid arthritis.
    Sanmartí R; Ruiz-Esquide V; Bastida C; Soy D
    Immunotherapy; 2018 Mar; 10(6):447-464. PubMed ID: 29495891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The association between interleukin-6 polymorphisms and rheumatoid arthritis: a meta-analysis.
    Lee YH; Bae SC; Choi SJ; Ji JD; Song GG
    Inflamm Res; 2012 Jul; 61(7):665-71. PubMed ID: 22427231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic Burden and Treatment Patterns of Cycling between Conventional Synthetic Disease-modifying Antirheumatic Drugs Among Biologic-treated Patients with Rheumatoid Arthritis.
    Betts KA; Griffith J; Ganguli A; Li N; Douglas K; Wu EQ
    Clin Ther; 2016 May; 38(5):1205-16. PubMed ID: 27045991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.